Source of the article: Siyu MedTech; Editor: Seven Kite
Reprint Requirements: Please indicate the source of the article at the beginning of the text, and it can be reprinted directly.
Annual Medical Technology Conference
Recently, SNEURO MEDICAL (hereinafter referred to as “SNEURO MEDICAL") announced the completion of a Series B+ financing round worth several hundred million yuan. This round was led by OrbiMed with participation from existing investor Boyuan Capital. The funds will primarily be used for SNEURO MEDICAL's new product development, clinical research, registration applications, core technology iteration, and commercial expansion.
Neuromodulation technology is one of the fastest-growing fields in medicine.Considered to be the future of chronic disease treatment,Neuromodulation devices can be divided intoImplantable NeurostimulatorAndTargeted Drug Infusion System。CurrentlyThe most widely used isImplantable Neurostimulation, Implantable neurostimulators can be subdivided into deep brain stimulators (DBS), spinal cord stimulators (SCS), sacral nerve stimulators (SNS/SNM), vagus nerve stimulators (VNS), hypoglossal nerve stimulators (HGNS), gastric electrical stimulators, and transcutaneous electrical nerve stimulators, depending on the different neural segments they modulate.Neuromodulation devices can be divided into implantable neurostimulators and targeted drug delivery systems.Among them, Spinal Cord Stimulation (SCS), Deep Brain Stimulation (DBS), and Vagus Nerve Stimulation (VNS) are the top three细分 markets.Spinal Cord Stimulation (SCS)Main Indications:Chronic pain, failed back surgery syndrome, ischemic pain, etc.Market Environment：Currently, the global prevalence of chronic pain exceeds 20%, with over 300 million patients in China, and this number is rapidly increasing by 10 to 20 million annually.Deep Brain Stimulation (DBS)Main Indications:Parkinson's disease, essential tremor, dystonia, obsessive-compulsive disorder, etc.CityField Environment：China has more than 3 million Parkinson's disease patients, accounting for over a quarter of the world's total. Additionally, approximately 100,000 new cases are reported each year. By 2030, the total number of Parkinson's disease patients in China is expected to reach 5 million, nearly half of the global total.Vagus Nerve Stimulation (VNS)Main Indications:Epilepsy, obesity, depression, etc.Market Environment:Epidemiological data shows that there are approximately 50 million epilepsy patients globally, with nearly 1/5 in China, and there are currently over 3 million patients with drug-resistant epilepsy (DRE) in China.Market SizeMarkets and Markets predicted,The global neuromodulation market will grow from USD 5.8 billion in 2020 to USD 8.8 billion in 2025.，In recent years, the global neuromodulation market has been growing rapidly at a CAGR of around 8%.In细分领域上Among them, Spinal Cord Stimulation (SCS), Deep Brain Stimulation (DBS), and Vagus Nerve Stimulation (VNS) are the top three细分 markets, accounting for the majority of the overall market.85.38%, accounting for respectively54.67%、16.52%And14.19%。In the competitive landscape:In the Spinal Cord Stimulation (SCS) market segment:Medtronic, Abbott, and Boston Scientific divide the market into three parts,Medtronic (34%), Abbott (29%), Boston Scientific (23%), Nevro (13%), Nuvectra (13%)In the Deep Brain Stimulation (DBS)细分 market:Medtronic Dominates,Medtronic (82%), Abbott (10%), Boston Scientific (8%)In the Vagus Nerve Stimulation (VNS) segment market：LivaNova（83%）、NeuroPace（17%）Data source: QYR Healthcare Research Center,Meddevicetracker Report,2018Foreign medical device giants, due to their mature technology and early market entry, occupy an absolutely leading position in the market. DBS therapy entered China in 1998 and has since developed over a history of more than 20 years.As Chinese-produced enterprises such as PINS and SceneRay continue to innovate and break through, the original monopoly pattern is gradually being broken.
# About SNEURO MEDICAL
As a neuromodulation platform company, SNEURO MEDICAL is committed to the independent research, development, and production of medical devices in the fields of implantable neurostimulation and brain-computer interfaces, with the goal of continuously providing affordable neuromodulation treatment products for patients. The core team has over a decade of comprehensive experience in the research and production of implantable devices, as well as strong capabilities in product development, system building, and commercial expansion.
Since its registration and establishment in December 2018, the companyApplied for more than 100 related patents and software copyrights, owning three major technology platforms: short-term implantation, rechargeable IPG, and wireless power carrying. Mastering key core technologies such as electrodes, chips, wireless charging, and algorithms, with the core ability to continuously launch new products and technologies in the field of neuromodulation.。
Currently, for different diseases, the company has successfully developed multiple implantable neurostimulators. Some products have completed clinical enrollment, and some are about to initiate clinical trials.
In the field of chronic pain, SNEURO MEDICAL aims to launch SCS products with higher accessibility, independently developing two major systems: the SCS system and Peripheral Nerve Stimulation (PNS). The SCS is used for long-term implantation to treat intractable pain, while the PNS is for short-term implantation, serving as a temporary and short-term peripheral nerve modulation system to alleviate acute and chronic pain.
As of the date of publication, the company's financing history is as follows:
As of the date of publication, the following partial patent information of the company has been queried:
Global MedTech Top 100: 2023 Global MedTech TOP100
2023 Global MedTech Industry Contribution Award
2023 Global Medical Technology Innovation Award
2023 Global MedTech Pioneer Award
2023 Global Innovative Medical Device Award
Global Leading Medical Device Companies | Dynamic CollectionChina Medical Device Listed Companies | Dynamic CollectionEditor-in-Chief | Zhao Qing Reviewed by | Yi He
